ClinicalTrials.gg
Not yet recruitingNCT07409350Updated Nov 10, 2026

A Social Network Approach to Improve HIV Prevention and Substance Use Treatment For People Who Use Drugs

An interventional study of LINKED and Group Intervention in Substance Use and HIV Prevention, sponsored by NYU Langone Health. Not yet recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
398
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Substance-Related Disorders by NYU Langone Health — 3 open to participants now, 5 under way, none of them phase 3. Substance-Related Disorders · NYU Langone Health.

Planned enrollment
3rd of 11
398 · median 87
Started
2027
with 1 other
No phase
8 of 14
3 open now
Registered
14th of 14
by date

Among the 14 studies in Substance-Related Disorders by NYU Langone Health, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2027, is one of 8 with no phase, and was the 14th registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

3 of the 14 studies in Substance-Related Disorders by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Substance-Related Disorders by NYU Langone Health, or all of them as a file.
02

Study summary

This study includes finalization of the LINKED social network intervention to improve PrEP and MOUD uptake among people who inject drugs (PWID) in collaboration with an Expert Advisory Board and staff (N=16) at The Sidewalk Project (TSP), followed by a Hybrid Type II cluster randomized trial of the LINKED intervention (versus an equal-attention control) among N=372 people who inject drugs, with 6- and 12-month follow-up assessment of PrEP and MOUD uptake. The investigators will also evaluate implementation outcomes to inform future sustainable implementation of LINKED in harm reduction organizations.

03

Conditions studied

  • Substance Use
  • HIV Prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Aim 1 - Virtual Focus Group

  • Is 18 years or older
  • Is a current TSP staff
  • Is capable and willing to provide consent

Aim 2 - Intervention

  • 18 years or older
  • Spend majority of their time in the Los Angeles, CA area where recruited
  • Able to complete surveys and group sessions in English
  • Self-report to have injected drugs in the past 3 months
  • Self-reported negative serostatus
  • Not currently on PrEP or MOUD
  • Not pregnant
  • If a network recruit: presents a valid recruitment coupon
  • Is capable and willing to provide consent

Aim 3 - Virtual Focus Group/Surveys

  • Is 18 years or older
  • Is a current TSP staff
  • Is capable and willing to provide consent

Exclusion criteria

Exclusion Criteria:

Aims 1 and 3:

  • Individuals who are not current TSP staff members will be excluded from participation.

Aim 2:

  • Under age 18;
  • Does not spend majority of time in the Los Angeles, CA area where recruited;
  • Unable to complete surveys and groups sessions in English;
  • Does not self-report injecting drugs in past 3 months;
  • Self-reported positive serostatus
  • Currently on PrEP or MOUD
  • Currently pregnant
  • If a network recruit: does not present a valid recruitment coupon
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
398 participants (estimated)

Study arms

  • Experimental
    LINKED Intervention

    Participants randomized to the LINKED arm will receive a peer change agent intervention consisting of a 3-hour workshop divided into four learning and practice modules.

    Behavioral: LINKED

  • Active comparator
    Equal-Attention Control

    Participants randomized to the equal attention control group will receive a group intervention facilitated by trained study staff.

    Behavioral: Group Intervention

Interventions

  • BehavioralLINKED

    LINKED is a theory-driven social network intervention (SNI) that leverages peer influence within the social networks of people who inject drugs (PWID) to disseminate information, encourage communication, and increase pre-exposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD) uptake and persistence in harm reduction organization (HRO) settings.

  • BehavioralGroup Intervention

    Group intervention facilitated by trained study staff that supports critical thinking about what constitutes low, medium, and high risks for HIV and overdose.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with PrEP Uptake

    Measured via filled PrEP prescription.

    Time frame: Month 6

  2. Percentage of Participants with PrEP Uptake

    Measured via filled PrEP prescription.

    Time frame: Month 12

  3. Percentage of Participants with MOUD Uptake

    Measured via filled MOUD prescription or buprenorphine, methadone, or naltrexone enrollment.

    Time frame: Month 6

  4. Percentage of Participants with MOUD Uptake

    Measured via filled MOUD prescription or buprenorphine, methadone, or naltrexone enrollment.

    Time frame: Month 12

  5. Percentage of Participants with PrEP Adherence

    Measured via urine immunoassays to test for oral PrEP.

    Time frame: Month 6

  6. Percentage of Participants with PrEP Adherence

    Measured via urine immunoassays to test for oral PrEP.

    Time frame: Month 12

  7. Percentage of Participants with MOUD Adherence

    Measured via urinalysis to test for metabolites for MOUD.

    Time frame: Month 6

  8. Percentage of Participants with MOUD Adherence

    Measured via urinalysis to test for metabolites for MOUD.

    Time frame: Month 12

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: Suzan.Walters@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Suzan.Walters@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.

Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 23 months is below that.

Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 13, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07409350
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Suzan Walters, PhD
Contact
Suzan.Walters@nyulangone.org
951-443-6351
Suzan Walters, PhD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion